Welcome • User Guide
ToS • Privacy • Canary
Donate • Bugs • License

©2024 Poal.co

1.1K

It's a conspiracy theory, goyim! Just a cohencidence! Found the hint in the book on Pfizer-BioNTech, I'm currently reading. They later switched to Ultrafiltration.

https://www.thermofisher.com/de/de/home/industrial/pharma-biopharma/nucleic-acid-therapeutic-development-solutions/mrna-therapeutic-resources/mrna-synthesis-reagents/magnetic-beads-mrna-production.html https://archive.ph/3VIPo

Dynabeads magnetic beads for mRNA synthesis and purification offer:

  • Flexibility—choice of DNA template for mRNA in vitro transcription with greater flexibility of design and amplification method
  • Reusability—reuse of the DNA template at least six times for minimized plasmid prep and reduced hands-on time
  • Automation—simplified, accelerated construct screening and reaction optimization ...

Magnetic beads for protein purification https://www.cytivalifesciences.com/en/us/solutions/genomics/knowledge-center/magnetic-bead-guide/mag-beads-for-protein-purification https://archive.ph/9Rcl6

Magnetic beads are used to purify single proteins, large protein complexes, antibodies and for high-throughput purifications. Magnetic beads based on chromatography resins provide functions of the resin with the convenience and ease-of-use of magnetic beads. Mag Sepharose beads, for example, are a convenient alternative to Sepharose columns. With a range of available ligands, these beads can simplify sample preparation of proteins and peptides prior to analysis. ...

Thermo Fisher Scientific, BioNTech ink licensing agreement https://www.drugdiscoverynews.com/thermo-fisher-scientific-biontech-ink-licensing-agreement-13125 https://archive.ph/u09Ek

WALTHAM, Mass.—Thermo Fisher Scientific and BioNTech have teamed up in a four-year, nonexclusive licensing agreement centered on the supply of critical raw materials for manufacturing immunotherapy vaccine candidates. Per the terms of the deal, Thermo Fisher will provide BioNTech with nucleotides, enzymes and other raw materials necessary for BioNTech's messenger RNA (mRNA) manufacturing platform. This agreement also provides BioNTech with rights to apply Thermo Fisher's technologies in conjunction with its clinical and commercial manufacturing processes. Specific financial details were not disclosed. ...

It's a conspiracy theory, goyim! Just a cohencidence! Found the hint in the book on Pfizer-BioNTech, I'm currently reading. They later switched to Ultrafiltration. https://www.thermofisher.com/de/de/home/industrial/pharma-biopharma/nucleic-acid-therapeutic-development-solutions/mrna-therapeutic-resources/mrna-synthesis-reagents/magnetic-beads-mrna-production.html https://archive.ph/3VIPo >Dynabeads magnetic beads for mRNA synthesis and purification offer: > - Flexibility—choice of DNA template for mRNA in vitro transcription with greater flexibility of design and amplification method - Reusability—reuse of the DNA template at least six times for minimized plasmid prep and reduced hands-on time - Automation—simplified, accelerated construct screening and reaction optimization ... Magnetic beads for protein purification https://www.cytivalifesciences.com/en/us/solutions/genomics/knowledge-center/magnetic-bead-guide/mag-beads-for-protein-purification https://archive.ph/9Rcl6 >Magnetic beads are used to purify single proteins, large protein complexes, antibodies and for high-throughput purifications. Magnetic beads based on chromatography resins provide functions of the resin with the convenience and ease-of-use of magnetic beads. Mag Sepharose beads, for example, are a convenient alternative to Sepharose columns. With a range of available ligands, these beads can simplify sample preparation of proteins and peptides prior to analysis. ... Thermo Fisher Scientific, BioNTech ink licensing agreement https://www.drugdiscoverynews.com/thermo-fisher-scientific-biontech-ink-licensing-agreement-13125 https://archive.ph/u09Ek >WALTHAM, Mass.—Thermo Fisher Scientific and BioNTech have teamed up in a four-year, nonexclusive licensing agreement centered on the supply of critical raw materials for manufacturing immunotherapy vaccine candidates. Per the terms of the deal, Thermo Fisher will provide BioNTech with nucleotides, enzymes and other raw materials necessary for BioNTech's messenger RNA (mRNA) manufacturing platform. This agreement also provides BioNTech with rights to apply Thermo Fisher's technologies in conjunction with its clinical and commercial manufacturing processes. Specific financial details were not disclosed. ...
You are currently inside a comment thread.
Click here to see all the comments (4).
[–] • 1 pt

Cool. All I ever saw was people claiming this phenomenon happening at the injection site. Maybe whatever was paramagnetic or diamagnetic existed in higher concentrations there?

I know this might amount to nothing. My ears just perked up, when I read of this old story in Stebel's relatively new book.

Older article I found: https://asia.nikkei.com/Spotlight/Coronavirus/COVID-vaccines/1.6m-Moderna-doses-withdrawn-in-Japan-over-contamination

YUMIKO URASAKI and YUKO NOMURA, Nikkei staff writersAugust 26, 2021 04:48 JST Updated on August 26, 2021 15:22 JST TOKYO/ NEW YORK -- About 1.6 million doses of Moderna's coronavirus vaccine have been taken out of use in Japan because of contamination reported in some vials, the Ministry of Health, Labor and Welfare said early Thursday.

Several vaccination centers have reported that vaccine vials contained foreign matter, according to an announcement from the ministry, which added it will seek to minimize the impact of the withdrawal on the country's inoculation program.

The ministry said later in the day that the substance that had been mixed in may have been metal. "It's a substance that reacts to magnets," a ministry official said. "It could be metal."

Takeda Pharmaceutical handles distribution of the U.S.-developed Moderna vaccine in Japan.

Nasdaq-listed Moderna confirmed receiving "several complaints of particulate matter" in vaccine vials distributed in Japan but said it had found "no safety or efficacy issues" related to these reports.